AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.
Reviewing Late-Breaking Research From AAD 2024
ReV Up Your Vitiligo Treatment Strategies
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Melanoma and the Wrong Site
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy